Biotechnology · Healthcare
Chairman, Board Member, CEO, COO
2020-11-01–present
Equibles does not estimate personal net worth.
Get an email with a short summary when Abeona Therapeutics Inc. publishes a filing, an earnings call transcript or a press release.
Get ABEO alertsMichael Amoroso is recorded as Board Member at Abeona Therapeutics Inc. (ABEO) since April 6, 2023, CEO at Abeona Therapeutics Inc. (ABEO) since March 19, 2021, COO at Abeona Therapeutics Inc. (ABEO) since November 1, 2020 and Chairman at Abeona Therapeutics Inc. (ABEO). The newest filing on record that lists Michael Amoroso as Chairman at Abeona Therapeutics Inc. (ABEO) is dated April 27, 2026. Abeona Therapeutics Inc. reported in an 8-K filed June 12, 2026 that Michael Amoroso resigned as member of the Board of Directors, effective June 11, 2026. Abeona Therapeutics Inc. reported in an 8-K filed April 11, 2023 that Michael Amoroso was appointed Chairman of the Board, effective April 6, 2023. The proxy statement of Abeona Therapeutics Inc. reports total compensation of $1,499,160 for Michael Amoroso in fiscal 2020, including a base salary of $219,071. Michael Amoroso has spoken on 4 earnings calls across 1 company, most recently for Abeona Therapeutics Inc. on July 28, 2021. Abeona Therapeutics Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Abeona Therapeutics Inc. includes Vishwas Seshadri (CEO and Board Member), Brian J.G. Pereira (Chairman and Board Member), Edward Carr (CFO) and 7 others.
“On June 11, 2026, Michael Amoroso resigned as a member of the Board of Directors (the "Board") of Abeona Therapeutics Inc. (the "Company") effective immediately.”
“Also on April 6, 2023, Michael Amoroso, Chairman of the Board, relinquished his seat as a Class 2 director and was immediately appointed as a Class 1 director by the Board to stand for reelection at the 2023 Annual Shareholder Meeting.”
“We're all excited to be with you today, and I hope this call finds you and your loved ones safe in these still uncertain times.”
“Good morning to our investor community who are excited to spend some time with you this morning, thank you for joining us. As I approach the midpoint of my first 100 days in the job as CEO, I wanted to start by reviewing three key strategic priorities for Abeona and our team.”
“It's a pleasure to be with you today for our Q4 and full year call. We're enthusiastic about Abeona's progress in developing our novel gene and cell therapies for underserved patient populations, and we remain committed to execution; 2021 is a year for delivery.”
“The Abeona team is excited to be with you this morning. We, at Abeona, remain committed to pursuing the development of our portfolio of advanced and early-stage programs toward providing our novel gene and cell therapies to patients who currently have no approved treatment options.”
2023-04-06–present
2021-03-19–present
2020-11-01–present
Source not stated
Start not stated–present
Last confirmed April 27, 2026
Start not stated–2026-06-11
Start not stated–2021-10-14
Biotechnology · Healthcare
Chairman, Board Member, CEO, COO
2020-11-01–present
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2020 | Abeona Therapeutics Inc. (ABEO) | Former President and Chief Executive Officer Fair value of option awards is calculated under ASC 718 as of the grant date using the Black-Scholes option-pricing model and as of the repricing date using a Hull-White I lattice model. Employees are assumed to exercise their options. The determination of the fair value of share-based payment awards made on the date of grant is affected by our Common Stock price as well as assumptions regarding a number of complex and subjective variables. Our assumptions in determining fair value are described in Note 11 of Notes to Consolidated Financial Statements in Part II, Item 8 of the Annual Report. | $219,071 | $1,499,160 |